RADIATION THERAPY TECHNIQUES AND COMBINATION TREATMENTS FOR SARCOMA
Professor Angela Hong, Director and
co-Chair of Scientific Advisory Committee,
Australia and New Zealand Sarcoma Association (ANZSA)
RESEARCHER PROFILE
Filmed Sydney, Australia | January 2025
Professor Angela Hong MBBS, MMed, PhD, FRANZCR is a Professor at Sydney Medical School of the University of Sydney. She is a radiation oncologist and has been a member of the Multidisciplinary Bone and Soft Tissue Tumour Clinic at Royal Prince Alfred Hospital/Chris O’Brien Lifehouse for the past 15 years.
She is also the Director and co-chair of the Scientific Advisory Committee for the Australia and New Zealand Sarcoma Association (ANZSA), a non-profit organisation aimed at enhancing treatment outcomes for sarcoma patients across Australia and New Zealand.
As a radiation oncologist located in Sydney, Australia, Professor Hong is focused on treating patients with bone and soft tissue sarcoma. And as a clinician scientist, her research focuses on developing innovative radiation therapy technique and combination treatments to improve the outcome for patients with sarcoma.
After earning her medical degree from the University of Sydney, Angela undertook an 18-month fellowship in the United States to gain additional experience before returning to Sydney to start her formal training in radiation oncology. She later completed her PhD, concentrating on radiosensitivity in skin cancer sarcoma.
Professor Hong believes in a multidisciplinary approach to managing sarcoma, given its rarity and the complexities involved in diagnosis and treatment. She is actively involved in clinical research and recently contributed to an international trial led by Sarcoma Alliance for Research through Collaboration (SARC) in the United States and the Australia and New Zealand Sarcoma Association (ANZSA) in Australia. The trial examined the advantages of including immunotherapy in the treatment regimen for high-risk soft tissue sarcoma, resulting in a notable improvement in two-year disease-free survival rates.
-
Investigating invasive lobular carcinoma and metaplastic breast cancer sub-types
Assoc Prof McCart Reed is the scientific lead on an MRFF-funded (Medical Research Future Fund) genomics program investigating the potential for the application of Whole Genome Sequencing in the breast cancer care pathway in Australia, ‘Q-IMPROvE’. She applies genomics and spatial transcriptomics methodologies to archival clinical samples to understand the differences between tumour types and their potential for treatment. Amy is passionate about clinical research, biobanking and precision oncology. In addition to her breast cancer research portfolio, she is on the steering committee for the Brisbane Breast Bank and the Scientific Advisory Board for Breast Cancer Trials.
-
Personalised approaches to lung therapy
Dr. Adams’ research focus is on lung cancer, which is the deadliest of all cancers worldwide. He is working towards developing personalised approaches to pinpoint a therapy that is going to be most effective for the person with that disease. Dr. Adams’ research is focusing on chemotherapy and targeted therapy, and he is trying to identify upfront which of those tumours are likely to be resistant to the therapy. He then identifies strategies that will resensitize or increase the sensitivity of the tumour to the standard of care that is targeted therapy or chemotherapy.
-
Newborn screening for congenital hypothyroidism
Assoc Prof Jack is passionate about the health and wellbeing of children and adolescents, with diverse research areas including the impacts of family friendly workplace initiatives, screening and management of thyroid disorders in infants and children. She supports her First Nations colleagues on Indigenous-led research projects funded by the Medical Research Future Fund, aiming to improve the social and emotional wellbeing of First Nations Children. Through her clinical and academic roles, Assoc Prof Jack hopes to make a positive difference to the health and well-being of children and their families.
